Melinda French Gates has announced a groundbreaking $100 million commitment to accelerate women’s health research through a new partnership with Wellcome Leap, marking one of the largest single investments in addressing the chronic underfunding of medical conditions affecting women. The September 10, 2025 announcement represents a significant milestone in efforts to close the gender health gap that has persisted for decades in medical research.
The partnership between Pivotal, French Gates’ philanthropic organization, and Wellcome Leap will focus on delivering breakthroughs in areas with the highest burdens of morbidity and mortality for women, including cardiovascular health, autoimmune disease, and mental health conditions. This investment builds on alarming statistics showing that women spend an average of nine years more in poor health compared to men, representing 25% more time in compromised health status.
Revolutionary Research Model Promises Faster Results
The collaboration will utilize Wellcome Leap’s proven DARPA-inspired model, which is designed to produce breakthrough results in years rather than decades. Under the leadership of CEO Regina E. Dugan, former Director of the U.S. Defense Advanced Research Projects Agency and the first woman to lead that organization, Wellcome Leap has already demonstrated success in accelerating health innovations globally.
The funding will support the launch of two new women’s health programs beginning in 2026, bringing Wellcome Leap’s total investment in women’s health to $250 million. This represents a significant step toward the organization’s ambitious goal of raising $1 billion in philanthropic capital dedicated to addressing under-researched conditions that disproportionately impact women throughout their lives.
French Gates emphasized the urgency of this investment during her announcement, stating that women’s health has been chronically underfunded and under-researched, resulting in poorly understood conditions that affect millions globally. The initiative aims to address the stark reality that only 1 percent of global health research funding was allocated to women’s health conditions beyond cancer in 2020.
Addressing Critical Health Gaps with Economic Impact
The economic implications of closing the women’s health gap are substantial, with potential benefits exceeding $1 trillion annually by 2040 according to research from the World Economic Forum and McKinsey. This economic argument strengthens the case for increased investment in women’s health research, demonstrating that addressing these gaps benefits not only individual women but entire economies.
The partnership specifically targets conditions where women experience health issues differently, disproportionately, or uniquely compared to men. Cardiovascular disease, for example, often presents differently in women and has been historically under-studied in female populations. Similarly, autoimmune diseases affect women at significantly higher rates than men, yet research has often failed to account for these gender-specific patterns.
Mental health represents another critical focus area, particularly given the higher rates of depression and anxiety disorders among women, especially during reproductive years and life transitions such as menopause. The research programs will aim to develop better diagnostics, treatments, and preventive interventions specifically designed for women’s unique physiological and hormonal profiles.
Wellcome Leap’s track record in women’s health includes existing programs focused on reducing stillbirth rates by half, decreasing women’s lifetime Alzheimer’s risk by 50 percent, and dramatically shortening the average diagnosis time for heavy menstrual bleeding from five years to five months. These programs have already shown promising early results, including the development of maternal blood tests that can predict conditions leading to stillbirth with greater than 80 percent accuracy as early as 12 weeks of pregnancy.
The announcement comes at a critical time when awareness of gender disparities in medical research is growing, but funding remains inadequate to address the scope of the problem. French Gates, who stepped down from the Gates Foundation in 2024 to focus on her own philanthropic initiatives, has made women’s health a central priority of her work through Pivotal.
This latest commitment builds on French Gates’ October 2024 pledge of $250 million toward organizations improving women’s mental and physical well-being through her Action for Women’s Health initiative. The recipients of that earlier funding are scheduled to be announced in November 2025, creating a comprehensive approach to addressing multiple aspects of women’s health simultaneously.